Osteogenesis Imperfecta Treatment Global Market Report 2025

The osteogenesis imperfecta treatment market size has grown steadily in recent years. It will grow from $0.89 billion in 2024 to $0.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this historical growth include a rise in clinical trials focused on OI-specific medications, increased spending on rare disease healthcare, enhanced emphasis on personalized and regenerative treatments, broader access to genetic screening and counseling services, and strengthened partnerships between pharmaceutical and biotechnology firms.

The osteogenesis imperfecta treatment market size is expected to see steady growth in the next few years. It will grow to $1.11 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. Projected growth drivers include a rising number of OI cases, improved awareness and diagnostic rates of genetic conditions, surging demand for efficient therapies targeting bone health, expanded funding for research in rare disease treatment, and increased innovation in monoclonal antibody development. Key trends anticipated during the forecast period include progress in monoclonal antibody engineering, innovations in 3D bone diagnostic and imaging technologies, breakthroughs in advanced drug delivery mechanisms, evolving stem cell and regenerative treatment solutions, and greater adoption of telehealth platforms for managing patients remotely.

The rising prevalence of osteogenesis imperfecta is contributing significantly to the growth of the osteogenesis imperfecta treatment market. This genetic disorder, characterized by fragile bones that break easily due to defective or insufficient type I collagen, is being detected more frequently owing to improved genetic testing and heightened diagnostic awareness. These advancements have led to the identification of cases that were previously undiagnosed. Treatments for osteogenesis imperfecta focus on strengthening bones, reducing the risk of fractures, managing symptoms, and improving patients' mobility and overall quality of life. For example, in June 2022, the Parliament of the United Kingdom reported that approximately 5,000 people in the UK were affected by osteogenesis imperfecta. As such, the increasing number of diagnosed cases is playing a key role in driving market growth.

Companies in the osteogenesis imperfecta treatment market are increasingly focusing on advanced therapeutics, such as sclerostin inhibition therapy, to enhance bone formation and minimize the risk of fractures in patients. This approach uses monoclonal antibodies to block sclerostin, a protein that inhibits bone growth, thereby boosting bone mineral density and strength. For instance, in October 2024, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company based in the United States, received Breakthrough Therapy Designation from the FDA for its investigational drug setrusumab (UX143). Setrusumab is a fully human monoclonal antibody designed to inhibit sclerostin, encouraging new bone growth and improving bone strength to reduce the risk of fractures in patients with Types I, III, and IV of osteogenesis imperfecta aged two years and older.

In June 2022, Sirana Pharma GmbH, a biotechnology company based in Germany, entered into a collaboration with Pfizer Inc. to develop and validate new drug candidates aimed at the regenerative repair of muscle and bone tissue affected by osteogenesis imperfecta. This initiative utilizes Sirana’s proprietary microRNA-targeting platform. Pfizer Inc., a US-based pharmaceutical firm, is known for its wide-ranging treatments in areas such as vaccines, oncology, internal medicine, and rare diseases.

Major players in the osteogenesis imperfecta treatment market are Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., BioMarin Pharmaceutical Inc., Stada Arzneimittel AG, Alkem Laboratories Ltd., Ultragenyx Pharmaceutical Inc., OrthoPediatrics Corp., Ascendis Pharma A/S, Pfenex Inc., Mereo BioPharma Group PLC, and BioSenic SA.

North America was the largest region in the osteogenesis imperfecta treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in osteogenesis imperfecta treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the osteogenesis imperfecta treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Osteogenesis imperfecta treatment involves a comprehensive approach encompassing medical, surgical, and supportive care strategies to manage symptoms, enhance bone strength, minimize the risk of fractures, and improve the overall quality of life for individuals living with osteogenesis imperfecta (OI), a hereditary condition marked by fragile bones.

The primary treatment options for osteogenesis imperfecta include medication, surgery, physical therapy, and lifestyle changes. Medications involve the administration of pharmaceutical agents to treat or manage medical conditions. In the context of OI, drugs such as bisphosphonates, teriparatide, and monoclonal antibodies are utilized to fortify bones and lower the likelihood of fractures. These medications fall into categories such as teriparatide, denosumab, among others, and are administered through various routes, including subcutaneous, intravenous, and oral methods. Distribution occurs through hospital pharmacies, retail pharmacies, and online platforms, serving a range of end users like hospitals, homecare services, specialized clinics, and other medical facilities.

The osteogenesis imperfecta treatment market research report is one of a series of new reports that provides osteogenesis imperfecta treatment market statistics, including the osteogenesis imperfecta treatment industry's global market size, regional shares, competitors with the osteogenesis imperfecta treatment market share, detailed osteogenesis imperfecta treatment market segments, market trends and opportunities, and any further data you may need to thrive in the osteogenesis imperfecta treatment market. This osteogenesis imperfecta treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteogenesis imperfecta treatment market consists of revenues earned by entities by providing services such as physical therapy, occupational therapy, and orthopedic support. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteogenesis imperfecta treatment market also includes sales of bisphosphonates, intramedullary rods, and braces and splints. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.